Interactions Between Glycogen Synthase Kinase-3β Gene Polymorphisms, Negative Life Events, and Susceptibility to Major Depressive Disorder in a Chinese Population

Jiarun Yang1, Siyuan Ke2, Zhengxue Qiao2, Xiuxian Yang2, Xiaohui Qiu2, Xuejia Song2, Erying Zhao2, Jiawei Zhou2, Mingzhe Zhao2, Yanjie Yang2*, Deyu Fang3 and Depin Cao1*

1Department of Health Management, Public Health Institute, Harbin Medical University, Harbin, China, 2Department of Psychology, Public Health Institute, Harbin Medical University, Harbin, China, 3Northwestern University Feinberg School of Medicine, Evanston, IL, United States

Background: Recent studies suggest that glycogen synthase kinase (GSK)-3β is involved in the development of major depressive disorder (MDD). The aim of this study was to investigate the interaction between GSK-3β polymorphism (rs6438552, rs334558, and rs2199503) and negative life events in the pathogenesis of major depressive disorder (MDD).

Methods: DNA genotyping was performed on peripheral blood leukocytes in 550 patients with MDD and 552 age- and gender-matched controls. The frequency and severity of negative life events were assessed by the Life Events Scale (LES). A chi-square method was employed to assess the gene-environment interaction (GxE).

Results: Differences in rs6438552, rs334558, and rs2199503 genotype distributions were observed between MDD patients and controls. Significant GxE interactions between allelic variation of rs6438552, rs334558, and rs2199503 and negative life events were observed. Individuals with negative life events and carrying genotypes of rs6438552 A+, rs334558 A+, and rs2199503G+ have increased the risk of depression.

Conclusions: These results indicate that interactions between the GSK-3β rs6438552, rs334558, and rs2199503 polymorphisms and environment increases the risk of developing MDD.

Keywords: glycogen synthase kinase-3β, polymorphism, major depressive disorder, gene-environment interaction, negative life events

INTRODUCTION

Major depressive disorder (MDD) is a group of mental disorders characterized by persistent low emotions, often accompanied by slow thinking, delayed behavior, and various somatization symptoms (1). MDD has a high prevalence, high recurrence rate, and high suicide disability rate, but there is a low detection rate, low treatment rate and low cure rate. The lifetime prevalence of
MDD is 12–17% (2). Although the etiology of MDD remains unclear, a genetic component is likely to contribute to the development of MDD, with heritability ranging from 40 to 50% (3, 4). Thus, the identification of MDD susceptibility genes not only makes it easier to explore the etiology of depression, but also can better reduce the prevalence of depression and provide targeted treatment to patients.

As people continue to explore the hypothesis related to depression, namely the hypothesis of mental illness and neuroplasticity, related research on glycogen synthase kinase (GSK-3β) (a key regulator of neuronal function) has increased (5). Studies have shown that GSK-3β may be related to the pathogenesis of MDD. Previous studies have shown that GSK-3β may be environmentally sensitive. Studies have reported that the combined effects of BDNF and GSK-3β genes regulate the relationship between negative life events and MDD (6). In addition, the latest research also shows that inhibiting the activity of GSK-3β may affect the therapeutic effect of antidepressants. Treatment with antidepressants inhibits GSK-3β activity in the mouse brain (7, 8). In conclusion, GSK-3β may be a susceptibility gene for depression and is involved in the pathophysiological and therapeutic processes of MDD.

The GSK-3β gene is located on the chromosomal region, 3q13.3, and is widely expressed in all brain regions. After rapid anti-depression treatment with ketamine, the phosphorylation level of GSK-3β in plasma increases significantly, suggesting that GSK-3β may be involved in the mechanism underlying anti-depression (9). GSK-3β gene single nucleotide polymorphisms [SNPs] (rs6438552, rs2199503, and rs334558) are associated with symptoms of depression in the Chinese population (10). The rs6438552 allele is closely related to the superior temporal gyrus of patients with depression and the decline of gray brain volume in the right hippocampus, and it was suggested that GSK-3β could be a susceptibility gene to MDD in the Chinese Han population (11). Herein, we studied the association between GSK-3β SNPs with MDD and investigated the effects of common confounding factors in conjunction with the SNPs on the susceptibility to MDD.

Although 31–42% of MDD cases are affected by genetic susceptibility, external environmental factors also play a vital role in the pathogenesis of MDD (12). More and more studies have shown that stress is an important factor in inducing the onset of MDD (13, 14). It induces negative emotional experiences such as sadness, loneliness, anxiety, depression, etc. by affecting the cognitive evaluation system. This leads to a series of physiological, biochemical, and immune system changes. Studies have shown that patients with MDD experience more negative life events than normal people. Therefore, negative life events are important triggers of MDD. The more negative life events, the more serious the nature, the higher the incidence of MDD, and the more severe the symptoms of MDD. There is a relationship between quantity and response.

Therefore, the interaction between environmental and genetic factors is the key reason for the pathogenesis of MDD. The purpose of this study was to investigate the interaction between GSK-3 antidepressants and negative life events in Chinese population, and to determine whether this interaction is involved in the pathophysiological process of MDD.

MATERIALS AND METHODS

Subjects

The study included 550 patients with MDD and 552 healthy controls. Both the patients and the control group were Han residents in northern China.

The MDD group consisted of 165 males and 385 females [mean age, 44.53 years (S.D., 13.53); age range, 16–30 years]. All patients with depression had their first onset and underwent a structured interview by two experienced psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) to confirm MDD (15). The severity of depression was evaluated by a Chinese version of the 24-item Hamilton Rating Scale of Depression (HRSD-24). Patients with a minimum score of 21 were included in the study. Patients with other co-morbid axis-I disorders, a family history of genetic disease, neurologic diseases, and those who received an antidepressant medication within 4 weeks were excluded from the study.

The control group included 195 males and 357 females [mean age, 43.19 years (S.D., 9.08); age range, 16–30 years]. All subjects were recruited from the Physical Examination Center in the First Affiliated Hospital of Harbin Medical University. The Structured Clinical Interview for DSM-V (SCID) was used to exclude psychiatric diseases, neurologic illnesses, and alcohol or drug abuse. Controls were matched for age, gender, and level of education with the MDD patients. The study was approved by the Ethics Committee of the Harbin Medical University and all subjects gave written consent.

Assessment of Negative Life Events

The Life Events Scale (LES) was used to assess negative life events (16), which has been verified in Chinese population. LES questionnaire has a total of 48 questions, involving the following three factors: family life (28 questions); Work (12); Social and other aspects (7 items). Negative life events include bereavement, divorce, serious illness, housing and financial crises, unemployment, work stress and problems with co-workers. Their scores were assessed by the interviewees themselves, based on how they felt, to produce a total life events score. This scale evaluates life events in the following four aspects: time of occurrence (absence = 1; So > 1 year ago is equal to 2; In the past year = 3; And chronic = 4); Character (good = 1; Bad = 2); Effect on mood (absence = 1; Mild = 2; Gentle = 3; Serious = 4; And extreme = 5); Duration of influence (≤3 months =1; 3–6 months = 2; 6–12 months = 3; >12 months =4). The 75% percentile (2 points) was used as a threshold for high or low negative life events.

Abbreviations: GSK3β, Glycogen Synthase Kinase-3β; MDD, major depressive disorder; LES, Life Events Scale; BLAST, Basic Local Alignment Search Tool; HWE, Hardy-Weinberg equilibrium; GWAS, genome-wide association studies; SZ, schizophrenia; BD, bipolar disorder.
DNA Extraction and Genotyping
Genomic DNA was extracted from collected venous blood samples using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Union City, CA, USA) and the SNPs (rs6438552, rs2199503, and rs334558) of the GSK-3β gene were selected for subsequent studies. The primers used for PCR amplification were designed using Primer 5.0 software, and the specificity of a potential primer was checked using the Basic Local Alignment Search Tool (BLAST) provided by the National Center for Biotechnology Information. The samples using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Union City, CA, USA) and the SNPs (rs6438552, rs334558, and rs2199503 Polymorphisms of the GSK-3β gene are divided into two types {primitive β and 5′-TCTAAACCTAAAGAACCTTAAAGAACTTAG-3′ (forward) and 5′- TCTTTTTTGAGAAGGAGTG-3′ (reverse). The primers for amplifying the GSK-3β rs334558 fragments were 5′-TCAGGAAGTGTCCGCGTTTGGAGGAGGTGGAGGACGAGTAG-3′ (forward) and 5′-AAGGAGGTGGAGGACGAGTAG-3′ (reverse). Analyses of SNPs was performed using SNaPshot according to the manufacturer’s instructions.

Statistical Analysis
The SPSS package (version 20.0 for Windows) was used for data analyses. A chi-square ($\chi^2$) goodness-of-fit test was performed to test the Hardy-Weinberg equilibrium (HWE) for the genotypic distribution of SNP. The $\chi^2$-test was used to compare SNP genotype and allele frequencies between MDD patients and controls. The generalized multi-factor dimension reduction (GMDR) was performed to analyze gene $\times$ environment interactions. All tests were two-sided, and statistical significance was set at a $P < 0.05$.

RESULTS
Comparison of Demographic Data and Negative Life Events Between the Case and Control Groups
There was no significant difference between MDD patients and control subjects with respect to gender, age, and level of education.

| TABLE 1 | Demographic data of MDD and control groups. |
|-------------------|-------------------|-------------------|-------------------|
| MDD (n = 550)     | Control (n = 552) | $\chi^2$ | $p$       |
| Sex               |                   |          |           |
| Male              | 165 (30.00%)      | 196 (35.30%) | 3.553 | 0.069 |
| Female            | 385 (70.00%)      | 357 (64.70%) |            |       |
| Age               |                   |          |           |
| 16–30             | 111 (20.18%)      | 99 (17.93%) | 0.902 | 0.637 |
| 31–54             | 277 (50.36%)      | 286 (51.81%) |          |       |
| >54               | 162 (29.46%)      | 167 (30.36%) |          |       |
| Education         |                   |          |           |
| Junior school and below | 288 (52.36%) | 271 (49.09%) | 3.317 | 0.190 |
| Senior school and Junior college | 191 (34.73%) | 220 (39.86%) |          |       |
| College and above | 71 (12.91%)       | 61 (11.05%) |          |       |

Effect of GSK-3β rs6438552, rs334558, and rs2199503 on MDD Susceptibility
The genotypic distributions of the GSK-3β polymorphisms conformed to the HWE for controls. Comparison of genotypes and alleles of the GSK-3β rs6438552, rs334558, and rs2199503 gene polymorphisms between the depression and control groups were summarized in Table 3. The genotype frequency distribution differences of the GSK-3β rs6438552, rs334558, and rs2199503 gene polymorphisms between the case and control groups were statistically significant ($P < 0.05$). The allele frequency distribution of the GSK-3β rs6438552, rs334558, and rs2199503 gene polymorphisms between the case and control groups was statistically significant ($P < 0.05$).

Combined Effects of GSK3β rs6438552, rs334558, and rs2199503 Polymorphisms and Negative Life Events on MDD
According to the dominant genetic model, the three SNPs of the GSK-3β gene are divided into two types {primitive type and mutant type [rs6438552 A$^-$ (GG), rs6438552 A$^+$ (AG+AA); rs334558 A$^-$ (GG), rs334558 A$^+$ (AG+AA); rs2199503 G$^-$ (GG), and rs2199503 G$^+$ (AG+GG)]}. GMDR was used to analyze the interaction between the GSK3β rs6438552, rs334558, and rs2199503 gene polymorphisms with negative life events and depression, and the results showed that there are interactions between GSK-3β rs6438552, rs334558, and rs2199503 polymorphisms and negative life events. Individuals with negative life events and rs6438552 A$^+$, rs334558 A$^+$, and
rs2199503G+ genotypes are at increased risk for depression ($P < 0.05$; Table 4).

**DISCUSSION**

Several lines of evidence indicate that GSK-3β is a good candidate for MDD susceptibility. In this study we determined whether or not common SNPs in the GSK-3β gene are associated with MDD and whether or not these sites have interactions with negative life events. The results showed that there were interactions between negative life events and GSK-3β rs6438552, rs334558, and rs2199503 polymorphisms. Thus, individuals suffering from negative life events and carrying rs6438552 A+, rs334558 A+, and rs2199503G+ genotypes are at increased risk for depression.

Our results suggest that GSK-3β rs6438552, rs334558, and rs2199503 polymorphisms are a susceptibility site for GSK-3β gene regions (15 SNPs detected). The study also found that rs6438552 was associated with gray matter volume in the right hippocampus and bilateral superior temporal gyrus (20). Taken together, these findings suggest that SNP rs6438552 of GSK-3β may mediate the risk of MDD by destroying neural connections. This finding is consistent with our findings. At the same time, we also found that rs2199503 and rs334558 had associations with MDD. A study by Jin et al. (22) in the Chinese Han population showed that rs2199503 is closely related to depression. This finding is related to the neurotrophic factor hypothesis for depression. Of note, the association between the rs2199503 single nucleotide polymorphism and the onset of depression through a large-sample case-control study [1,045 cases of depression vs. 1,235 cases of healthy controls; (22)], which is consistent with our results. Inkster et al. (10), however, did not find a correlation between rs2199503 SNP and gray matter volume in a study on the correlation between the GSK3β gene polymorphism and brain structure in patients with depression. For that reason, our study warrants replication in future studies. As a functional polymorphism within the GSK-3β promoter region, the GSK-3β rs334558 polymorphism might be a potential risk factor for MDD. A controlled study of 1,045 patients with MDD and 1,235 healthy volunteers found that rs334558 was associated with MDD in GSK3β patients (23). And this locus is a functional SNP that plays a role in the promoter. The A allele (primary allele) has previously been found to be associated with high GSK3β expression. Allele (A) of rs334558 may transmit the risk of MDD, and there was no significant heterogeneity in allele model (24). In addition, the work of Levchenko et al. also confirms that the GSK3β gene polymorphism rs334558 may play a key role as a genetic and pharmacological biomarker in MDD (25). These conclusions provide the basis for our future research.

---

**TABLE 3** Comparison of genotypes and alleles of GSK-3β rs6438552, rs334558, and rs2199503 gene polymorphisms between the depression and control groups.

| SNPs      | Group   | Genotype frequencies | p   | Allele frequencies | p   |
|-----------|---------|----------------------|-----|--------------------|-----|
| rs6438552 | MDD     | AA 132 (24.0)         |     | A 580 (52.7)       |     |
|           | Control | AG 316 (57.5)        |     | G 520 (47.3)       |     |
| rs334558  | MDD     | GA 109 (19.8)         |     | A 518 (47.1)       |     |
|           | Control | GG 300 (54.6)        |     | G 582 (52.9)       |     |
| rs2199503 | MDD     | AA 97 (17.6)          |     | A 487 (44.3)       |     |
|           | Control | AG 293 (53.3)        |     | A 613 (55.7)       |     |

**TABLE 4** GMDR analysis of gene-environmental interactions in MD patients and controls.

| No. of factors considered | Best combination | Prediction error | Cross-validation consistency | P-value |
|--------------------------|------------------|-----------------|-----------------------------|---------|
| 3                        | rs334558A*, rs6438552A*, negative life events | 0.3626 | 9/10 | 0.001 |
| 4                        | rs334558A*, rs6438552A*, rs2199503G*, negative life events | 0.3672 | 10/10 | 0.001 |
In addition, genetic factors have been shown to influence stress exposure (26). Genetic factors increase the risk of developing MDD by choosing high-risk environments. Although there have been a large number of studies on GSK-3β gene polymorphism in MDD patients, little attention has been paid to the interaction between GSK-3β gene polymorphism and negative sexual life events in these patients. Gene-environment interaction studies can explore how environmental factors influence depression. Our results showed that there was an interaction between rs6438552, rs334558, and rs2199503 polymorphism and negative life events in GSK-3β. This conclusion can be explained by diathesis-stress model (5). The model assumes that individuals with environmental susceptibility genes are more likely to develop MDD when they experience negative life events. Lin et al. (27) found that the interaction between GSK-3β rs2199503 and negative life events increased the risk of metabolic syndrome. A number of studies have shown that metabolic abnormalities occur in people with depression and the two diseases are mutually causal. Yang et al. (6) demonstrated a correlation between the interaction between GSK-3β rs2199503 and negative life events and the incidence of depression in a case-control study. These findings are all consistent with our findings.

This study has some limitations. First, the sample size is relatively small. Secondly, LES was filled in subjectively by the interviewees and collected questionnaires retrospectively. Therefore, there may be a bias in the recall, susceptible to subjective influence.

**CONCLUSION**

In summary, the present study indicated that an interaction between GSK-3β rs6438552, rs334558, and rs2199503 polymorphisms and environmental factors increases the risk of MDD. Further studies are necessary to replicate our results in larger populations and other ethnic groups, as well as to elucidate the underlying mechanism of gene × environment interactions involved in MDD.

**DATA AVAILABILITY STATEMENT**

The datasets analyzed in this article are not publicly available. Requests to access the datasets should be directed to yanjie1965@163.com.

**ETHICS STATEMENT**

The study was approved by the Ethics Committee of the Harbin Medical University and all subjects gave written consent. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

YY, DC, and DF conceived and designed the study, supervised the analysis, and interpreted the data. XY and XQ supervised the analysis, interpreted the data, and wrote the preliminary manuscript. ZQ, XS, and EZ supervised the data collection by JZ and MZ. SK and JY performed the test administration, compiled the data, and wrote the preliminary manuscript. All authors contributed to the writing and review of the manuscript and approved the final version.

**FUNDING**

This research was supported by the National Natural Science Foundation of China (81773536) to YY and the Fundamental Research Funds for State Universities of Heilongjiang Province (2017JCZX23) to EZ.

**ACKNOWLEDGMENTS**

The psychiatrists from the First Affiliated Hospital of Harbin Medical University are thanked for their contributions and participation by all the subjects. We thank International Science Editing for editing this manuscript.

**REFERENCES**

1. Wang C, Wu H, Chen F, Xu J, Li H, Li H, et al. Disrupted functional connectivity patterns of the insula subregions in drug-free major depressive disorder. J Affect Disord. (2018) 234:S0165032717318359. doi: 10.1016/j.jad.2017.12.033
2. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X. An excitatory synapse hypothesis of depression. Trends Neurosci. (2015) 38:279–94. doi: 10.1016/j.tins.2015.03.003
3. Gasperz R, Lamers F, Wittenberg G, Beekman AT, van Hemert AM, Schoevers RA, et al. The role of anxious distress in immune dysregulation in patients with major depressive disorder. Transl Psychiatry. (2017) 7:1–12. doi: 10.1038/s41398-017-0016-3
4. Liu S, Sun N, Xu Y, Yang C, Ren Y, Liu Z, et al. Possible association of the GSK3β gene with the anxiety symptoms of major depressive disorder and P300 waveform. Genetic Test Mol Biomark. (2012) 16:1382–9. doi: 10.1089/gtmb.2012.0227
5. O’Leary O, Nolan Y. Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders. CNS Drugs. (2015) 29:1–15. doi: 10.1007/s40263-014-0213-z
6. Yang C, Xu Y, Sun N, Ren Y, Liu Z, Cao X, et al. The combined effects of the BDNF and GSK3B genes modulate the relationship between negative life events and major depressive disorder. Brain Res. (2010) 1355:1–6. doi: 10.1016/j.brainres.2010.07.079
7. Chiu CH, Chyau CC, Chen CC, Lee LY, Chen WP, Liu JL, et al. Erinacine A enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice. Int J Mol Sci. (2018) 19:341. doi: 10.3390/ijms19020341
8. Roh MS, Eom TY, Zmijewska AA, De SP, Roth KA, Jope RS. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry. (2005) 57:278–86. doi: 10.1016/j.biopsych.2004.10.039
9. Rybakowski JK, Abramowicz M. The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. Int J Bipolar Disord. (2013) 1:8. doi: 10.1186/2194-7511-1-8
10. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, et al. Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch General Psychiatry. (2009) 66:721. doi: 10.1001/archgenpsychiatry.2009.70

11. Fukuda T, Kokubu S, Ohle S, Sasanuma H, Kanomata K, Yoneyama K, et al. Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a GSK3β-dependent and β-catenin-independent mechanism. Differentiation. (2010) 80:46–52. doi: 10.1016/j.diff.2010.05.002

12. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. (2013) 18:497. doi: 10.1038/mp.2012.21

13. Bale TL. Stress sensitivity and the development of affective disorders. Hormones Behav. (2006) 50:529–33. doi: 10.1016/j.yhbeh.2006.06.033

14. Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety – insights from human genetic studies. Mol Psychiatry. (2009) 15:574–88. doi: 10.1038/mp.2009.141

15. Zhao MZ, Yang JR, Qiu XH, Yang XX, Qiao ZX, Wang L, et al. Life event scale(LES). Rating scales for mental health. Ment. Health. (1999) 12:101–6.

16. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry. (2007) 61:240–5. doi: 10.1016/j.biopsych.2006.04.036

17. Claude H, Richard K, Simon L. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem. (2010) 104:1433–9. doi: 10.1111/j.1471-4159.2007.05194.x

18. Benedetti F, Poletti S, Radaelli D, Locatelli C, Pirovano A, Lorenti C, et al. Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder. Psychopharmacology. (2015) 232:1325–36. doi: 10.1007/s00213-014-3770-4

19. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, et al. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage. (2010) 53:908–17. doi: 10.1016/j.neuroimage.2010.02.065

20. Tsai SJ, Liou YJ, Hong CJ, Yu YW, Chen TJ. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J. (2008) 8:384. doi: 10.1038/sj.tpj.6500486

21. Jin H, Shen M, Miao X, Tang H, Liu D, Zhu L-Q, GSK-3 beta polymorphism discriminates bipolar disorder and schizophrenia. A systematic meta-analysis. Mol Neurobiol. (2013) 48:404–11. doi: 10.1007/s12035-013-8414-x

22. Costemale-Lacoste J-F, Colle R, Martin S, El Asmar K, Loeb E, Feve B, et al. Glycogen synthase kinase-3β genetic polymorphisms and insomnia in depressed patients: a prospective study. J Affect Disord. (2018) 240:230–6. doi: 10.1016/j.jad.2018.07.062

23. Yang DS, and YL Z. Life event scale (LES). Rating scales for mental health. Chin. Ment. Health. (1999) 12:101–6.

24. Kendler KS, Baker JH. Genetic influences on measures of the environment: a systematic review. Psychol Med. (2007) 37:613–26. doi: 10.1017/S0033291706009524

25. Li X, Liu S, Wang L, Sun N, Yang C, Liu Z, Li X. The gender-specific association of rs334558 in gsk3β with major depressive disorder. Medicine. (2017) 96:e5928. doi: 10.1097/MD.0000000000005928

26. Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bohdan NA, Wilpert B, et al. The functional variant rs334558 of gsk3β is associated with remission in patients with depressive disorders. Pharmacogenomics Pers Med. (2018) 11:121–6. doi: 10.2147/PGPM.S174123

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Ke, Qiao, Yang, Qiu, Song, Zhao, Zhou, Zhao, Yang, Fang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.